Ustekinumab-Kfce

Introduction Overview

Generic Name

ustekinumab-kfce

Brand Name

Yesintek

Dosage Form

subcutaneous injection single-dose prefilled syringe (45 mg/0.5 mL or 90 mg/mL), subcutaneous injection single-dose vial (45 mg/0.5 mL), injection for intravenous infusion single-dose vial (130 mg/26 mL)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption: Yesintek (ustekinumab-kfce), administered subcutaneously or intravenously, exhibits a pharmacokinetic profile characterized by gradual absorption when given subcutaneously. Following subcutaneous injection, peak serum concentrations are generally achieved within 7 to 14 days. The bioavailability of the subcutaneous route is estimated to be approximately 57–72%, influenced by factors such as injection site and patient-specific variables. Intravenous administration results in immediate systemic availability, achieving peak serum levels rapidly. The absorption process is not significantly affected by food intake or concomitant medications, facilitating consistent therapeutic exposure.

Distribution: Ustekinumab distributes primarily within the vascular and interstitial compartments given its large molecular size as a monoclonal antibody (~149 kDa). The volume of distribution approximates plasma volume, typically around 6–9 liters. Binding predominantly occurs within the extracellular space; tissue penetration is moderate reflecting typical protein biologic behavior. The drug specifically targets interleukin subunits present in inflammatory sites, contributing to its efficacy. Minimal binding to plasma proteins other than its target interleukins is noted.

Metabolism: As a monoclonal antibody, Yesintek undergoes proteolytic catabolism via reticuloendothelial and cellular pathways rather than hepatic metabolism. It is degraded into small peptides and amino acids by ubiquitous proteases without involvement of cytochrome P450 enzymes. This metabolism pathway reduces risks of cytochrome P450-mediated drug-drug interactions. The immune system plays a critical role in clearance via binding to target antigens or nonspecific catabolic pathways.

Elimination: The elimination half-life of Yesintek is approximately 19 to 28 days, supporting dosing intervals of 8 to 12 weeks depending on indication and body weight. Clearance occurs primarily via proteolytic degradation within cellular reticuloendothelial systems. No significant renal or hepatic excretion has been observed. The long half-life facilitates sustained suppression of IL-12 and IL-23 mediated inflammation with infrequent dosing. Clinical monitoring is advised especially in patients with altered immune function or comorbid conditions affecting protein degradation.

Dosage Forms

Available Dosage Forms: Yesintek is available in multiple parenteral formulations tailored for subcutaneous and intravenous administration:
- Prefilled single-dose syringe for subcutaneous injection: 45 mg/0.5 mL
- Prefilled single-dose syringe for subcutaneous injection: 90 mg/mL
- Single-dose vial for subcutaneous injection: 45 mg/0.5 mL
- Single-dose vial for intravenous infusion: 130 mg/26 mL (equivalent to 5 mg/mL concentration)

Dosages for Adults and Adolescents: Dosage regimens are weight-based and vary by indication.
- For adults and children 6 years and older with plaque psoriasis or psoriatic arthritis:
- ≤ 100 kg body weight: 45 mg subcutaneously at week 0, week 4, then every 12 weeks.
- > 100 kg body weight: 90 mg subcutaneously at week 0, week 4, then every 12 weeks.
- For adults with Crohn's disease or ulcerative colitis:
- Initial intravenous infusion dose based on weight: up to 55 kg - 260 mg (2 vials);
55 to 85 kg - 390 mg (3 vials);
>85 kg - 520 mg (4 vials).
- Follow-up maintenance doses: 90 mg subcutaneously 8 weeks after initial IV infusion, then every 8 weeks thereafter.

Specific Patient Populations: Pediatric patients aged 6 years and older have dosing regimens aligned with weight categories similar to adults for psoriasis and psoriatic arthritis. No specific dosage adjustments have been established for renal or hepatic impairment due to protein metabolism pathways. Caution and clinical judgment are advised for immunocompromised or elderly patients, with careful monitoring for adverse reactions.

Mechanism Of Action

Yesintek (ustekinumab-kfce) exerts its therapeutic effects through targeted inhibition of specific pro-inflammatory cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23). The drug is a human monoclonal antibody that binds with high affinity to the p40 protein subunit shared by both IL-12 and IL-23. This binding prevents these cytokines from interacting with their corresponding cell surface receptors on immune cells.

At a cellular level, IL-12 and IL-23 are key modulators in the differentiation, activation, and proliferation of T-helper cells, particularly Th1 and Th17 subsets, which are implicated in the pathogenesis of autoimmune and inflammatory diseases. By neutralizing the activity of IL-12 and IL-23, Yesintek downregulates the inflammatory cascade, reducing the release of downstream effectors such as interferon-gamma and tumor necrosis factor-alpha that perpetuate tissue inflammation.

This immunomodulation leads to decreased infiltration of inflammatory cells into affected tissues, reduction in swelling, pain, and pathological skin changes characteristic of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Furthermore, Yesintek's blockade of these cytokines mitigates the autoimmune destruction and chronic inflammation associated with these disorders.

Comparatively, other biologics like TNF-alpha inhibitors target a different branch of the inflammatory cascade, whereas Yesintek’s IL-12/IL-23 inhibition provides a distinct and complementary therapeutic approach. Clinical studies demonstrate that Yesintek's mechanism results in sustained remission and improved clinical outcomes with a favorable safety profile. Ongoing research continues to explore the full spectrum of inflammatory pathways modulated by IL-12 and IL-23 inhibition, reinforcing Yesintek’s role in managing immune-mediated diseases.

Pharmacological Actions

Selective binding and inhibition of the p40 subunit common to interleukin-12 (IL-12) and interleukin-23 (IL-23)
Suppression of Th1 and Th17 cell differentiation and activation pathways involved in autoimmune inflammation
Reduction of pro-inflammatory cytokine production including interferon-gamma and tumor necrosis factor-alpha
Immunomodulatory effect leading to decreased immune cell infiltration in affected tissues
Alleviation of chronic inflammation associated with plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Long half-life enabling sustained therapeutic effects with periodic dosing
Minimal involvement with cytochrome P450 metabolism reducing drug interaction potential
Decreased activity of pathogenic immune responses without broad immunosuppression
Potential to reduce symptoms such as pain, swelling, redness, and skin lesions
Biosimilar to Stelara, providing equal potency and safety in immunomodulation

Therapeutic Or Clinical Uses

Treatment of moderate to severe plaque psoriasis in adults and children aged 6 years and older
Management of active psoriatic arthritis in adults and pediatric patients (6 years and above)
Induction and maintenance therapy for moderate to severe Crohn's disease in adults
Induction and maintenance therapy for moderate to severe ulcerative colitis in adults
Option for patients who require systemic or phototherapy for plaque psoriasis
Alternative biologic therapy for patients with autoimmune inflammatory conditions unresponsive to traditional treatments
Use in patients who may benefit from IL-12/IL-23 cytokine pathway blockade
Treatment strategy for reducing inflammation, pain, and skin lesions associated with autoimmune disorders
Appropriate for patients who require infrequent dosing schedules due to long half-life
Biosimilar biologic providing access to a cost-effective therapy with comparable efficacy and safety
Used as part of combination therapy with immunosuppressants in selected clinical scenarios
Management of immune-mediated chronic inflammatory conditions requiring biologic agents
Prescribed under physician supervision with consideration of patient immunization and infection status

Side Or Adverse Effects

Common: nasal congestion and upper respiratory tract symptoms including runny nose and sore throat
Headache and general fatigue or tiredness
Upper respiratory infections such as common cold or influenza
Serious infections including tuberculosis, bacterial, viral, and fungal infections requiring immediate medical attention
Allergic reactions ranging from mild hypersensitivity to severe anaphylaxis with symptoms like hives, chest pain, and swelling
Increased risk of skin cancers and other malignancies in patients receiving therapy
Potential development of posterior reversible encephalopathy syndrome (PRES), characterized by headaches, confusion, seizures, or vision disturbances
Lung inflammation and serious pneumonia reported with ustekinumab treatment
Injection site reactions including redness, bruising, tenderness, or pain
Possible exacerbation or new onset of psoriasis or skin lesions
Impaired immune response to vaccinations, particularly live vaccines
Risk of worsening latent infections or reactivation of tuberculosis
Potential for immunogenicity and formation of anti-drug antibodies leading to decreased efficacy
Gastrointestinal symptoms such as diarrhea and abdominal pain may occur during Crohn's or ulcerative colitis treatment
Rare neurological or systemic autoimmune phenomena may be observed

Precautions

Screen for latent tuberculosis infection prior to initiating Yesintek therapy
Avoid use in patients with active serious infections or chronic infections unless medically cleared
Vaccinate patients fully according to immunization guidelines prior to treatment; avoid live vaccines during and one year post-therapy
Caution in patients with a history of malignancy or skin cancer; perform dermatological examinations regularly
Monitor for new or worsening symptoms of infection throughout treatment
Exercise caution in patients receiving concurrent immunosuppressive therapies to reduce additive immunosuppression
Assess pregnancy status prior to initiation; use only if benefits justify potential risks and enroll in pregnancy registries if exposed during pregnancy
Consider breastfeeding risks as drug passes into breast milk; discuss alternative feeding options
Monitor for neurological symptoms suggestive of PRES and discontinue therapy if confirmed
Avoid injections into areas of skin that are bruised, tender, red or indurated
Educate patients on proper injection techniques if administered at home
Regularly assess liver and renal function indirectly by clinical status as formal adjustments are not established
Use caution in patients undergoing allergy immunotherapy due to potential increased allergic reaction risks
Promptly report any signs of allergic reactions or serious adverse events to healthcare providers
Ensure safe disposal of syringes and vials to prevent contamination and infection

Warnings

Yesintek may increase the risk of serious infections including tuberculosis and opportunistic infections
Do not initiate treatment in patients with active infections until they are adequately treated
Avoid live vaccines during treatment and for at least one year following discontinuation
Potential development of certain cancers, including skin cancers, during therapy necessitating ongoing monitoring
Risk of life-threatening anaphylactic or severe allergic reactions during or after administration
Possible development of posterior reversible encephalopathy syndrome (PRES), which can be fatal if untreated
Use caution with concomitant immunosuppressants to reduce increased risk of infections and malignancies
Close monitoring required for pulmonary symptoms indicative of pneumonia or lung inflammation
Risk of decreased effectiveness of immunizations administered during treatment
Patients should be advised to report any symptoms suggestive of infections or neurological abnormalities immediately
Do not co-administer BCG vaccine within 1 year before, during, or 1 year after Yesintek treatment
Household contacts receiving live vaccines may pose a risk of virus transmission to the patient
Serious hypersensitivity reactions, including serum sickness-like reactions, may occur
Not studied extensively in patients with impaired immune systems or concurrent autoimmune conditions
Discontinuation or dose adjustment might be necessary based on adverse event severity

Contraindication

Known hypersensitivity to ustekinumab or any component of Yesintek formulations
Previous allergic reaction to any interleukin inhibitor including Stelara, Selarsdi, Pyzchiva, Otulfi, Wezlana, and other ustekinumab biosimilars
Presence of active serious infections including sepsis, tuberculosis, or fungal infections at treatment initiation
Receipt of live vaccines within 1 year prior to initiation or planned live vaccine administration during therapy
History of hypersensitivity to monoclonal antibodies or polysorbate 80 (an excipient in Yesintek)
Patients with documented malignancy where immunosuppressive therapy is contraindicated, unless benefit outweighs risk
Use in populations with immunodeficiency syndromes or chronic infections may be contraindicated pending risk evaluation
Known severe allergic reactions related to prior immunomodulatory biologic treatment
Concurrent use with other biologics that target interleukins or immune pathways without clinical justification
Any condition where suppression of IL-12 and IL-23 would predispose to high morbidity or mortality risks

Drug Interactions

Concomitant use with immunosuppressants such as azathioprine, cyclosporine, methotrexate, sirolimus, and tacrolimus may increase risk of infections and adverse events
Interactions with oral corticosteroids like prednisone and dexamethasone may potentiate immunosuppression
CYP450-metabolized drugs with narrow therapeutic indices (e.g., warfarin, cyclosporine) require careful monitoring as immune modulation may influence metabolism
Anticoagulants (blood thinners) such as warfarin may need close INR monitoring during coadministration
Allergy immunotherapy effectiveness may be reduced, and risk of allergic reactions increased during Yesintek treatment
Concomitant administration with live vaccines is contraindicated due to risk of vaccine-derived infection
Limited data on interactions with herbal supplements; caution advised due to potential immune modulation
No significant pharmacokinetic interaction observed due to proteolytic metabolism of Yesintek
Potential diminished efficacy of non-live vaccines administered during treatment
Concurrent use with other biologics targeting inflammatory pathways requires clinical justification and monitoring
Drug interactions may alter pharmacodynamics leading to increased infection risk or adverse immunological effects
Patients should inform healthcare providers of all medications including over-the-counter drugs and supplements
Monitoring for enhanced adverse effect profiles is recommended when combining with other immunomodulators
No formal studies on interactions with antibiotics or antivirals, but vigilance advised due to infection risk

Preparations Of The Drug

Yesintek 45 mg/0.5 mL single-dose prefilled syringe for subcutaneous injection
Yesintek 90 mg/mL single-dose prefilled syringe for subcutaneous injection
Yesintek 45 mg/0.5 mL single-dose vial for subcutaneous injection
Yesintek 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion
All formulations contain inactive ingredients including histidine, L-histidine monohydrochloride monohydrate, Polysorbate 80, sucrose, hydrochloric acid, and sodium hydroxide for pH adjustment
Intravenous formulation additionally contains edetate disodium and methionine as stabilizers
Prefilled syringes are designed for ease of use with patient or caregiver administration following training
Single-dose vials require reconstitution and preparation by healthcare professionals for accurate dosing
Packaging protects from light and requires refrigerated storage between 2°C and 8°C (36°F to 46°F)
Prefilled syringes may be stored at room temperature up to 30°C (86°F) for up to 30 days once removed from refrigeration
All preparations are for single-use only; reuse or sharing of needles or syringes is contraindicated
Proper disposal of needles and syringes is mandated to prevent contamination or infection
Product labeling includes detailed instructions for storage, handling, and administration
Manufactured under strict biosimilar regulatory standards by Biocon Biologics Inc.
Biosimilar to the reference product Stelara, providing equivalent clinical efficacy and safety